HMGB1 program (Bio3)

N/A

Report date: 2025/01/26 19:14:06
NME

Base Information

Drug NameHMGB1 program (Bio3)
Drug Alias NameHigh mobility group protein B1 modulator (180 Life Sciences/University of Oxford)anti-TNF (180 Life Sciences/University of Oxford)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor inhibitorsHigh Mobility Group Protein B1 modulators
TargetsTumor necrosis factorHigh Mobility Group Protein B1
Therapy Area/IndicationsFibrosisLiver Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator Companies180 Life Sciences Corp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Oxford180 Life Sciences Corp
Inactive CompaniesN/A
Active IndicationsFibrosisLiver Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A